ALK and neoplasm: All common neuroblastoma ALK hotspot mutations were represented in tumor sequencing results for eligibility, including F1174C/L (51%), R1275Q (33%) and F1245Y/L (12%), one ALK amplification and one pathologic D1276_R1279 ALK-activating mutation (Table 1).